Oculis Upsizes ATM to $125M and Posts Narrower Q3 Loss With Runway Into 2H 2029
OCS is trading near its 52-week low of $7.11 (11% above the low) on elevated volume (2.1× avg).
Summary
Oculis raised the ceiling on its existing at-the-market program from $100 million to $125 million and reported a nine-month net loss of CHF 57.1 million, with CHF 210.3 million in cash and short-term investments it says funds operations into 2H 2029.
Key Events · Financing and Capital Events · OCS
-
ATM Capacity Raised to $125 Million
Amendment No. 1 to the March 4, 2026 sales agreement with Leerink Partners lifts the at-the-market ceiling from $100.0 million to $125.0 million. As of the filing date, no shares have been sold under the amendment.
-
Nine-Month Loss Narrows to CHF 57.1 Million
Net loss fell from CHF 75.4 million a year earlier, but the improvement is non-cash: a CHF 7.3 million warrant fair-value gain and a CHF 3.7 million FX gain. Operating loss widened to CHF 68.9 million from CHF 61.0 million.
-
Cash of CHF 210.3 Million, Runway Into 2H 2029
Cash, cash equivalents and short-term investments totaled CHF 210.3 million ($252.0 million) at September 30, 2026, down from CHF 213.0 million at year-end 2025 after CHF 54.5 million of operating cash burn.
-
PREDICT-1 Topline Due Around Year-End 2026
Patient randomization is complete in the 176-patient registrational trial of Licaminlimab in TNFR1-mediated dry eye disease, with topline results expected around year-end 2026; IND clearance for Privosegtor in acute MS relapses is expected in Q4 2026.
Analysis · OCS · Life Sciences
The at-the-market program Oculis first set up on March 4, 2026 now carries $25 million of additional capacity, bringing the total to $125 million. No new shares were sold under the amendment — this is permission to sell, not a completed raise — but it gives the company a larger tap for funding the PIONEER-1 optic neuritis trial and the PREDICT-1 dry eye readout due around year-end 2026. On the earnings side, the nine-month loss narrowed to CHF 57.1 million from CHF 75.4 million, though that improvement came mostly from a CHF 7.3 million non-cash warrant remeasurement gain and a CHF 3.7 million FX gain, not from operations: operating loss actually widened to CHF 68.9 million from CHF 61.0 million. With cash of CHF 210.3 million ($252.0 million) stated to fund operations into the second half of 2029, the upsized ATM is opportunistic headroom rather than a survival move.
How filings like this one have moved
In the 30 days to Nov 17, 2026, 38% of the 3791 measured filings Wiseek scored 7 moved their stock by 5% or more by the next session's close. The median move was 0.00%. These are measured outcomes after filings of this importance, not a forecast for this one.
Measured one observation per ticker per day, after exclusions. Current figures: Filing Impact Tracker · open dataset
At the time of this filing, OCS was trading at $7.89 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $471M. The 52-week trading range was $7.11 to $34.48. This filing was assessed with neutral market sentiment and an importance score of 7 out of 10.